CD8A and neoplasm: Preclinical HCC models have demonstrated that personalized neoantigen vaccines combined with PD-1 inhibitors significantly enhanced CD8+ tissue-resident memory T cell infiltration, reduced regulatory T cells and monocytic myeloid-derived suppressor cells, and led to increased tumor regression overall [96].